Heart of Bath Medical Partnership Initiated as the first site in the UK for GMRx2 ACT

Last week we were delighted to initiate Heart of Bath Medical Partnership as the first site in the UK for the GMRx2 active controlled trial. This phase III trial will investigate George Medicines proprietary triple low-dose combination pill for the treatment of hypertension.
 
Approximately 500 patients are expected to be recruited from hospitals and GP practices across the UK. They will join 1,000 patients already being recruited across international sites including the US and Australia.
 
Another 24 sites will open across the UK in the coming weeks.


#clinicaltrial #clinicalresearch #imperialcollegelondon #ictuglobal #hypertension #lifesciences #globalhealth #GMRx2 #ARO

For further information regarding our services and how we can collaborate, please contact our team

News